Canada · Delayed Price · Currency is CAD Sernova Biotherapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A merger will create BetaNova Biotherapeutics, integrating advanced cell therapies and a proven delivery device to pursue a functional cure for type 1 diabetes. Clinical trials begin soon, with early efficacy data expected in 2027 and plans for broader patient impact.
-
BetaNova Biotherapeutics is formed from a merger, combining proprietary cell therapy, gene-editing, and implantable device technologies to target a functional cure for type 1 diabetes. The merger is structured as an equal partnership, with secured financing to reach key clinical and regulatory milestones, and plans for a NASDAQ listing in early next year.
Fiscal Year 2024
-
A regenerative medicine platform using a Cell Pouch system has shown promising results in Type 1 diabetes, with several patients achieving long-term insulin independence. Preclinical studies support the efficacy of iPSC-derived islet-like clusters, and new clinical trials are planned for 2026.